Please assess the completion status of the following clinical trial:

Trial Title: GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with previously untreated advanced stage, CD20-positive FL~* Patient with ECOG performance status 0, 1 or 2.~Exclusion Criteria:~* Patient with Grade 3b (aggressive) FL or any histology other than FL grade 1, 2 or 3a~* Patient who has previously received any prior therapy for lymphoma~* Patient with evidence of any uncontrolled, active infection (viral, bacterial or fungal).~* Patient with any malignancy within 5 years prior to date of randomization, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GP2013 (Type: EXPERIMENTAL): Type: Biological/Vaccine
- rituximab (Type: ACTIVE_COMPARATOR): Type: Biological/Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).